Rhythm Pharmaceuticals, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Rhythm Pharmaceuticals, Inc. Rhythm Pharmaceuticals, Inc. (RYTM) is a commercial-stage biopharmaceutical company focused on developing and commercializing precision medicines for rare neuroendocrine diseases, particularly those involving melanocortin-4 receptor (MC4R) pathway disorders that cause hyperphagia and severe obesity. The company's lead product, IMCIVREE (setmelanotide), an MC4R agonist, is approved by the FDA and European Commission for chronic weight management in patients with obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, as well as Bardet-Biedl syndrome (BBS); it targets root causes of insatiable hunger and early-onset obesity in these genetic conditions. Rhythm advances a pipeline including earlier-stage MC4R agonists such as RM-718 for weekly subcutaneous administration, bivamelagon (LB54640), an oral small molecule now in Phase 2 trials for acquired hypothalamic obesity following completion of enrollment, and setmelanotide expansions into Phase 3 trials for acquired hypothalamic obesity, Prader-Willi syndrome, and other MC4R-related disorders like POMC/LEPR heterozygous deficiency, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, and Alström syndrome. Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals operates primarily in the United States and Europe, with over 250 employees across North America and Europe; it generates revenue mainly from U.S. IMCIVREE sales, supplemented by international ex-U.S. growth and partnerships. The company maintains licensing and collaboration agreements with LG Chem, Ltd., Ipsen Pharma S.A.S., Camurus, RareStone Group Ltd., and Axovia Therapeutics to support global development and commercialization of its therapies. Recent developments include the 2023 acquisition of Xinvento and initiation of a Phase 3 trial in acquired hypothalamic obesity; the 2024 acquisition of oral MC4R agonist LB54640 from LG Chem Life Sciences and first patient dosing with RM-718; a January 2025 strategic partnership with Trispera Pharma Solutions in Turkey; a March 2025 research collaboration with the Raymond A. Wood Foundation on craniopharyngioma-related fatigue; enrollment completion in the Phase 2 bivamelagon trial with topline data expected in Q3 2025; and anticipated topline Phase 3 data in hypothalamic obesity in Q2 2025, alongside regulatory submissions and new trial enrollments in congenital hypothalamic obesity and Prader-Willi syndrome.
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
Why Is Rhythm Pharma Stock Jumping Today?
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Rhythm Pharmaceuticals: The Rare Obesity Platform Is Becoming A Commercial Engine
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
My Top 3 Stocks to Buy in May
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference